Skip to main content
OpenTrials
Completed

NCT Number: NCT02976298

Effects of Cerebellum or Supplementary Motor Area Functional Inactivation on Gait and Balance Control

In human, the physiology of gait and balance is not clearly established. By using functional imaging and electrophysiological techniques, various brain regions from the cortex to the midbrain area, including the cerebellum, have been identified as involved in such control. The specific role of these structures in both the capacity to go forward (locomotion) and stand upright (balance), but also in the different phases of the gait initiation process, are not known, however. In this study,the investigators aimed to assess the specific role of both the supplementary motor area (SMA) and the cerebellum in postural control during the initiation of gait. For this purpose, the investigators plan to study the gait initiation in 20 healthy subjects before and after functional inactivation (using inhibitory repetitive transcranial magnetic stimulation, rTMS) of the cerebellum or SMA. Biomechanical, kinematic and electromyographic parameters of the gait initiation will be recorded using a force platform, reflective markers with infrared cameras (VICON system) and lower limbs surface EMG electrodes.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

M.L.Welter

Paris, 75013, France

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18-70 years
  • agree to participate to the study with signature of the informed consent
  • heathy insurance
  • normal clinical exam

Exclusion criteria

  • previous medical history of neurological, rheumatological, orthopedic or psychiatric disorders
  • contra-indication to MRI or TMS
  • drug treatment that modifies the nervous central system excitability (antidepressant, antiepileptic, neuroleptic)
  • chronic alcoholism

Treatment and study plan

Transcranial magnetic stimulation

Other

comparison of different conditions of transcranial magnetic stimulation

Primary outcomes

  1. postural control during gait initiation

    Time frame: change between baseline and 5 minutes after transcranial magnetic stimulation

    braking capacity

Secondary outcomes

  1. duration of anticipatory postural adjustments

    Time frame: change between baseline and 5 minutes after transcranial magnetic stimulation

    duration

Other outcomes

  1. centre of foot pressure displacement during postural adjustments

    Time frame: change between baseline and 5 minutes after transcranial magnetic stimulation

    centre of foot pressure displacement measured by force platform

  2. step length

    Time frame: change between baseline and 5 minutes after transcranial magnetic stimulation

    step length

  3. step velocity

    Time frame: change between baseline and 5 minutes after transcranial magnetic stimulation

    step velocity

  4. duration of electromyographic activity of the tibialis anterior muscles

    Time frame: change between baseline and 5 minutes after magnetic transcranial stimulation

Sponsors and collaborators

Lead sponsor

Institut National de la Santé Et de la Recherche Médicale, France

Other Gov

Registry information

Official study title

Rôle du Cervelet et de l'Aire Motrice supplémentaire Dans le contrôle Postural au Cours de la Marche Chez l'Homme

Acronym: CERESMARCHE

Important dates

Study start
2013
Primary completion
2015
Study completion
2015
First posted
Nov 29, 2016
Registry last updated
Sep 2, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.